You are here

  • Home
  • Archive
  • Volume 75, Issue Suppl 2
  • FRI0230 Assessment of Safety, Pharmacokinetics and Pharmacodynamics of A Novel anti-CD40 Monoclonal antibody, CFZ533, in Healthy Volunteers and in Rheumatoid Arthritis Patients

Citation Tools

Article menu
Download PDFPDF
Poster Presentations
Rheumatoid arthritis - other biologic treatment
FRI0230 Assessment of Safety, Pharmacokinetics and Pharmacodynamics of A Novel anti-CD40 Monoclonal antibody, CFZ533, in Healthy Volunteers and in Rheumatoid Arthritis Patients

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Slade A, Koo P, He Y, et al
FRI0230 Assessment of Safety, Pharmacokinetics and Pharmacodynamics of A Novel anti-CD40 Monoclonal antibody, CFZ533, in Healthy Volunteers and in Rheumatoid Arthritis Patients
Annals of the Rheumatic Diseases 2016;75:516-517.